Themis Medicare Limited (NSE:THEMISMED)
102.44
+0.86 (0.85%)
Nov 11, 2026, 1:52 PM IST
Themis Medicare Revenue
Themis Medicare had revenue of 869.57M INR in the quarter ending June 30, 2026, a decrease of -10.88%. This brings the company's total for the last twelve months to 3.32B, down -12.75% year-over-year. In the fiscal year ending March 31, 2026, Themis Medicare had annual revenue of 3.42B, down -15.60%.
Revenue (ttm)
3.32B
Revenue Growth
-12.75%
P/S Ratio
2.83
Revenue / Employee
2.47M
Employees
1,340
Market Cap
9.46B
Revenue by Geography
- India 2.37B 69.7%
- Outside India 1.03B 30.3%
Fiscal year ended Mar 31, 2026 See the full Themis Medicare breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.42B | -632.76M | -15.60% |
| Mar 31, 2025 | 4.06B | 237.51M | 6.22% |
| Mar 31, 2024 | 3.82B | 274.38M | 7.74% |
| Mar 31, 2023 | 3.54B | -402.91M | -10.21% |
| Mar 31, 2022 | 3.95B | 1.64B | 71.07% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 19.09B |
| Windlas Biotech | 9.93B |
| Ind-Swift Laboratories | 7.64B |
| Sigachi Industries | 4.91B |
| Beta Drugs | 4.10B |
| Valiant Laboratories | 3.76B |
| Jagsonpal Pharmaceuticals | 3.16B |
| Amanta Healthcare | 3.04B |
Themis Medicare News
- 1 year ago - Themis Medicare shares surge nearly 2% following amalgamation announcement - Business Upturn